Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana Vivancos

Showing results (21-30 of 103) with videos related to

Pageof 11
Sort By:
Oncotarget|March 13, 2016
Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technologyMaider Ibarrola-Villava, Tania Fleitas, Marta J Llorca-Cardeñosa, et al.
Breast (Edinburgh, Scotland)|March 16, 2025
Identifying germline pathogenic variants in breast cancer using tumor sequencingMara Cruellas, Andri Papakonstantinou, Adrià López-Fernández, et al.
British Journal of Cancer|November 24, 2018
Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancerJesús García-Foncillas, Josep Tabernero, Elena Élez, et al.
Genome Medicine|March 30, 2018
Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterationsDavid Tamborero, Carlota Rubio-Perez, Jordi Deu-Pons, et al.
Molecular Cancer Therapeutics|June 23, 2012
Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trialsRodrigo Dienstmann, Danila Serpico, Jordi Rodon, et al.
Molecular Cancer Therapeutics|September 22, 2019
Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION TrialJaume Capdevila, Ignacio Matos, Francesco M Mancuso, et al.
British Journal of Cancer|October 2, 2021
Genetic evolution to tyrosine kinase inhibitory therapy in patients with EGFR-mutated non-small-cell lung cancerAlex Martinez-Marti, Enriqueta Felip, Francesco Mattia Mancuso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 30, 2024
Clinical Value of Liquid Biopsy in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma During Targeted TherapyAlberto González-Medina, Maria Vila-Casadesús, Marina Gomez-Rey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 19, 2022
ESMO Scale for Clinical Actionability of Molecular Targets Driving Targeted Treatment in Patients with CholangiocarcinomaHelena Verdaguer, Tamara Saurí, Daniel Alejandro Acosta, et al.
Frontiers in Oncology|October 7, 2021
Case Report: A Case Study Documenting the Activity of Atezolizumab in a PD-L1-Negative Triple-Negative Breast CancerFara Brasó-Maristany, Miriam Sansó, Nuria Chic, et al.
Pageof 11

Showing results (21-30 of 103) with videos related to

Sort By:
Pageof 11
Oncotarget|March 13, 2016
Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technologyMaider Ibarrola-Villava, Tania Fleitas, Marta J Llorca-Cardeñosa, et al.
Breast (Edinburgh, Scotland)|March 16, 2025
Identifying germline pathogenic variants in breast cancer using tumor sequencingMara Cruellas, Andri Papakonstantinou, Adrià López-Fernández, et al.
British Journal of Cancer|November 24, 2018
Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancerJesús García-Foncillas, Josep Tabernero, Elena Élez, et al.
Genome Medicine|March 30, 2018
Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterationsDavid Tamborero, Carlota Rubio-Perez, Jordi Deu-Pons, et al.
Molecular Cancer Therapeutics|June 23, 2012
Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trialsRodrigo Dienstmann, Danila Serpico, Jordi Rodon, et al.
Molecular Cancer Therapeutics|September 22, 2019
Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION TrialJaume Capdevila, Ignacio Matos, Francesco M Mancuso, et al.
British Journal of Cancer|October 2, 2021
Genetic evolution to tyrosine kinase inhibitory therapy in patients with EGFR-mutated non-small-cell lung cancerAlex Martinez-Marti, Enriqueta Felip, Francesco Mattia Mancuso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 30, 2024
Clinical Value of Liquid Biopsy in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma During Targeted TherapyAlberto González-Medina, Maria Vila-Casadesús, Marina Gomez-Rey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 19, 2022
ESMO Scale for Clinical Actionability of Molecular Targets Driving Targeted Treatment in Patients with CholangiocarcinomaHelena Verdaguer, Tamara Saurí, Daniel Alejandro Acosta, et al.
Frontiers in Oncology|October 7, 2021
Case Report: A Case Study Documenting the Activity of Atezolizumab in a PD-L1-Negative Triple-Negative Breast CancerFara Brasó-Maristany, Miriam Sansó, Nuria Chic, et al.
Pageof 11